###### Key questions

What is already known about this subject?
=========================================

-   Sildenafil is well tolerated in paediatric patients with pulmonary hypertension with little change in functional capacity as measured by peak oxygen consumption.

What does this study add?
=========================

-   This is the largest, randomised placebo controlled study reporting the effects of sildenafil on metabolic stress test parameters in children with pulmonary hypertension who are able to exercise.

-   Sildenafil appeared to improve short-term VE/VCO~2~ slope versus placebo but did not significantly improve PVO~2~ in treatment-naïve paediatric patients with pulmonary arterial hypertensionwho were able to exercise.

-   Additionally, we report on the safety of metabolic stress testing in a young population of patients with pulmonary hypertension which may help inform future clinical trials in this patient population.

How might this impact clinical practice?
========================================

-   Metabolic stress test is safe and can be repeated multiple times in this population. Other endpoints such as VE/VCO~2~ slope should be considered when planning future clinical trials.

Introduction {#s1}
============

Pulmonary arterial hypertension (PAH) is a rare and complex disease affecting both children and adults, resulting in an increase in pulmonary vascular resistance and subsequent right heart failure and death.[@R1] In children, PAH has previously been shown to carry a poor prognosis with a median untreated survival of only 10 months.[@R2] Although not wellstudied, the development of therapies for PAH and their subsequent use in children have been associated with a marked improvement in survival to over 60% at 10 years.[@R3] The Sildenafil in Treatment-Naïve Children, Aged 1--17 years, with Pulmonary Arterial Hypertension(STARTS-1 and 2) studies were the first randomised, double-blind studies to evaluate the efficacy of a therapy in children with PAH. Previously published results showed a trend towards improvement in the primary endpoint of percent change in peak oxygen consumption (VO~2~) for the combined sildenafil dose groups against placebo.[@R5]

The 6 min walk (6 MW) test is used to evaluate the efficacy of therapies for PAH and has been shown to correlate with survival.[@R7] One limitation of the 6 MW test is that it is effortdependent which can be variable in children.[@R9] Cardiopulmonary exercise testing (CPET) is an objective assessment of both maximal and submaximal exercise tolerance and has been performed safely and repeatedly in children, including those with PAH, and correlates with survival.[@R8] However, the peak VO~2~ is also dependent on exercise effort, and maximal effort can be difficult to attain in children. CPET however has the advantage of being able to determine whether a test is maximal, unlike the 6 MW test. Additionally, the slope of ventilation to carbon dioxide (VE/VCO~2~) production is unchanged throughout exercise, is effortindependent and predicts mortality in heart failure and patients with pulmonary hypertension.[@R12] Changes in VE/VCO~2~ slope in response to treatment have not been evaluated in children being treated for PAH. In this study, exercise data from the STARTS-1 and 2 studies was examined. Specifically, we evaluate the impact of sildenafil on CPET measures including peak VO~2~ and VE/VCO~2~ slope and report the 16-week and 1-year results of exercise testing.

Methods {#s2}
=======

The study designs of the STARTS-1 and 2 trials have been previously published.[@R5] In brief, STARTS-1 randomised patients with idiopathic, heritable or other (connective tissue disease or congenital heart disease) PAH between the ages of 1--17 to either placebo or low-dose, medium-dose or high-dose sildenafil, three times a day. Doses were dependent on body weight, with the goal to achieve inhibition of phosphodiesterase type 5 activity of 53%, 77% or 90%, respectively. The STARTS-2 trial was a continuation of STARTS-1. Patients who were initially randomised to receive sildenafil in STARTS-1 were maintained on their initial dose for STARTS-2; those initially receiving placebo in STARTS-1 were randomised to one of the three doses of sildenafil used in STARTS-1. During STARTS-2, changes in the sildenafil dose were allowed. In STARTS-1, the primary endpoint was percent change in peak VO~2~ normalised to body weight from baseline to 16 weeks. Secondary endpoints included change in PVO~2~ at 1 year, changes in VE/VCO~2~ slope at 16 weeks and 1 year, right heart haemodynamics, exercise duration and physical and psychosocial scales of the Child Health Questionnaire-Parent form 28.

To ensure high-quality data, CPET at each site was evaluated and qualified by a centralised exercise core laboratory. Sites were allowed to enrol patients only when approved by the core laboratory. Each site was required to acquire CPET data from two normal control (healthy) adults using a 20 W/min continuous ramp protocol. The gas exchange data were reviewed by the core laboratory and if values fell out of expected norms, the data were deemed unsuitable, and site qualification was rejected. Common reasons for a site to fail qualification included using the wrong ramp protocol, leaks in the gas exchange system or an improperlycalibrated ergometer. Sites that were rejected initially performed corrective changes and were retested until data were acceptable. Each site was required to retest one of their control subjects every 6 months to maintain quality.

Only children who were developmentally able to reliably perform CPET were evaluated for the primary endpoint. Developmental ability was determined by the investigator. Patients were able to be enrolled in the study if their peak VO~2~ was [\>]{.ul}10 and\<28 mL/kg/min. Each test began with a rest phase of up to 3 min until the respiratory exchange ratio (RER) was less than 0.8 and stable. Patients then began a 'warm-up' phase of unloaded cycling for 1--3 min at 60 revolutions/min followed by a 5 W/min (\<40 kg) or 10 W/min (\>40 kg) continuous ramp protocol. All patients were encouraged to exercise to maximum while maintaining a cadence of 50--60 revolutions/min. Other reasons to stop exercise included chest pain, presyncope or exercise-induced hypotension. Patients were monitored for at least 10 min after completing exercise, including a 3 min warm-down phase of unloaded cycling. Vital signs, Borg rate of perceived exertion and ECG were monitored throughout exercise and recovery.

Once the exercise test was performed, test data were sent to the exercise core laboratory for initial review to ensure an adequate test was performed prior to randomisation into the trial (peak exercise RER \>1.05 and/or an increase of 0.15 from baseline, linear increases in VO~2~, carbon dioxide production and ventilation). There was no predetermined goal for peak heart rate. CPET endpoints were determined by two independent, blinded physicians at the Core Lab. Disagreements were reconciled via discussion and mutual agreement.

Statistical analysis {#s2-1}
--------------------

The primary endpoint was evaluated using analysis of covariance (ANCOVA) in which the mean percent change from baseline in PVO~2~ at week 16 in the 3 sildenafil treatment groups (low, medium and high dose) was contrasted to that in the placebo group (with contrast coefficients 1/3, 1/3, 1/3 and −1). Comparisons of the individual dose groups to the placebo group were also made. The ANCOVA model included terms for treatment, baseline result, aetiology and weight group. Statistical hypothesis testing was performed at the two-sided 5% significance level. Similar analyses were conducted for treatment comparisons in percent change of VE/VCO~2~ slope from baseline at week 16. For STARTS-2, the percent change from baseline to 1 year for PVO~2~ and for VE/VCO~2~ slope was summarised with descriptive statistics for each STARTS-1treatment group. For other CPET parameters, including RER, end-tidal O~2~ and end-tidal CO~2~, percent change from baseline at week 16 and at year 1 was also summarised with descriptive statistics. VE/VCO~2~ slope was calculated as the slope of the best fit line for ventilation and carbon dioxide throughout the entire exercise duration.

Informed consent/assent was obtained from each subject (or subject's legally authorised representative).

Results {#s3}
=======

Of the 234 patients randomised and treated in the STARTS-1 trial, 115 patients (49%) were developmentally able to reliably perform CPET and thus had baseline readings. Reasons for not exercising included age \<7 (63) and developmental issues (trisomy 21 (31), couldnot reach pedals and various reasons including intolerance of mouthpiece and low physical activity. One hundred and six of these patients (92%) had evaluable PVO~2~ data at week 16 ([figure 1](#F1){ref-type="fig"}, machine failure/damage, n=3; discontinuation without final assessment, n=2; too ill, inadequate test data that were not repeated, lack of staff, not done in error, n=1 each). PVO~2~ data at year 1 were evaluable in 98 patients. One hundred and five patients had both evaluable PVO~2~ and VE/VCO~2~ slope data at week 16, and 100 patients had evaluable VE/VCO~2~ slope data at 1 year.

![Patients were assigned to one of three doses or placebo by weight and developmental ability to perform exercise testing. Not all patients able to perform exercise were tested due to a variety of factors.](openhrt-2019-001149f01){#F1}

[Table 1](#T1){ref-type="table"} shows the baseline characteristics of the patients. The age range of patients who could exercise was 5--17, and half were between the ages of 5 and 12. Most patients were female and all had idiopathic or heritable PAH or PAH associated with congenital heart disease. The majority of patients were WHO functional class II at baseline. Mean PVO~2~ at baseline was 17.6 (43.9% predicted), 18.1 (45.2% predicted) and 17.3 mL/kg/min (45.5% predicted) for the low-dose, medium-dose and high-dose sildenafil groups, respectively, versus 20.0 mL/kg/min (51.2% predicted) for the placebo group; similarly, the mean baseline VE/VCO~2~ slope was 50.1, 47.6 and 50.2 for the low-dose, medium-dose and high-dose sildenafil groups, respectively, versus 46.3 for the placebo group.

###### 

Demographic characteristics of patients able to exercise reliably

  --------------------------------------------------------------------------------------------------------------------------------
  Characteristic, mean (SD)                                         Placebo\*\     Sildenafil dose                  
                                                                    (n=30)                                          
  ----------------------------------------------------------------- -------------- ----------------- -------------- --------------
  Female sex, n (%)                                                 19 (63)        17 (61)           15 (54)        21 (72)

  Age, y, n (%)                                                                                                     

   5--12                                                            18 (60)        15 (54)           13 (46)        11 (38)

   13--17                                                           12 (40)        13 (46)           15 (54)        18 (62)

  Race---n (%)                                                                                                      

   White                                                            8 (27)         10 (36)           11 (39)        6 (21)

   Black                                                            2 (7)          0                 1 (4)          0

   Asian                                                            4 (13)         6 (21)            7 (25)         7 (24)

   Other                                                            16 (53)        12 (43)           9 (32)         16 (55)

  Weight, kg, mean (range)                                          37 (20--60)    42\               42\            37\
                                                                                   (21--105)         (23--106)      (15--61)

  BMI, kg/m^2^                                                      18 (3)         19 (6)            18 (4)         17 (3)

  WHO functional class, n (%)                                                                                       

   I                                                                10 (33)        5 (18)            8 (29)         6 (21)

   II                                                               17 (57)        15 (54)           13 (46)        18 (62)

   III                                                              3 (10)         8 (29)            7 (25)         5 (17)

  Aetiology, n (%)                                                                                                  

   IPAH/HPAH                                                        10 (33)        9 (32)            10 (36)        12 (41)

   APAH                                                             20 (67)        19 (68)           18 (64)        17 (59)

   Surgical repair†                                                 7 (23)         7 (25)            7 (25)         8 (28)

   Congenital systemic-to-pulmonary shunt withSaO~2~ ≥88% at rest   12 (40)        11 (39)           10 (36)        9 (31)

   Postrepair D-transpositionof great arteries                      1 (3)          1 (4)             1 (4)          0

  PVO~2~, mL/kg/min                                                 20.0 (3.8)     17.6 (4.4)        18.1 (4.8)     17.3 (3.6)

  VE/VCO~2~ slope                                                   46.3 (15.2)    50.1 (14.8)       47.6 (13.6)    50.2 (14.5)

  RER                                                               1.10 (0.13)    1.09 (0.08)       1.10 (0.12)    1.09 (0.09)

  Time to PVO~2~, s                                                 460 (141)      433 (127)         453 (140)      436 (106)

  Total ventilation, L/min                                          36.3 (13.0)    38.0 (13.4)       37.2 (16.2)    34.2 (14.1)

  End-tidal O~2~, mmHg                                              106.7 (20.2)   117.5 (15.7)      113.8 (14.7)   105.9 (21.3)

  End-tidal CO~2~, mmHg                                             26.3 (5.9)     23.5 (6.1)        27.9 (4.5)     23.4 (5.4)

  Anaerobic threshold, mL/kg/min                                    13.1 (2.8)     13.1 (3.8)        12.2 (4.4)     11.8 (2.9)

  Percent predicted PVO~2~                                          51.2 (11.9)    43.9 (10.0)       45.2 (12.0)    45.5 (10.7)
  --------------------------------------------------------------------------------------------------------------------------------

\*Twenty-nine subjects randomised to sildenafil low, medium and high dose in Sildenafil in Treatment-Naïve Children, Aged 1--17 years, with Pulmonary Arterial Hypertension.

†Surgical repairs included atrial septal defect, ventricular septal defect, patent ductus arteriosus, aortopulmonary window and others.

APAH, associated pulmonary arterial hypertension; BMI, body mass index; CPET, cardiopulmonary exercise test; HPAH, heritable PAH; IPAH, idiopathic pulmonary arterial hypertension; PAH, pulmonary arterial hypertension; PVO~2~, peak VO~2~; RER, respiratory exchange ratio; SaO~2~, systemic arterial oxygen saturation; VE/VCO~2~, ratio of ventilation to CO2 output; VO~2~, oxygen consumption.

Week 16 outcomes {#s3-1}
----------------

The primary endpoint, mean change in PVO~2~ in the combined sildenafil dose groups at week 16 compared with placebo, increased by 7.7%±4.0% (SE); p=0.056, 95% CI −0.2% to 15.6%). Compared with placebo, there were significant increases in mean PVO~2~ for the medium-dose group, but not for the low-dose or high-dose group.([table 2](#T2){ref-type="table"}) There was no change in PVO~2~ compared with baseline for the placebo group ([figure 2a](#F2){ref-type="fig"}). Similarly, compared with placebo, the VE/VCO~2~ slope improved, with a mean reduction in the combined sildenafil dose groups (±SE) of −9.7±2.6% (p\<0.001, 95% CI of the mean difference: −14.9% to −4.5%, [figure 3a](#F3){ref-type="fig"}).

###### 

Percent change from baseline in cardiopulmonary exercise parameters at week 16 and year 1 of Sildenafil in Treatment-Naïve Children, Aged 1--17 years, with Pulmonary Arterial Hypertension (STARTS-1/-2)

  CPET parameter                 Week 16   Year 1                                         
  ------------------------------ --------- -------- ------- ------- ------- ------ ------ -------
  Peak VO~2~                                                                              
   N                             29        24       26      27      23      25     25     27
   Mean                          0.5       6.4      13.4    10.6    −0.2    12.4   7.3    5.3
   SD                            15.9      20.2     19.5    15.5    19.9    22.8   33.8   23.5
  VE/VCO~2~ slope                                                                         
   N                             29        23       26      27      23      25     24     26
   Mean                          2.7       −8       −8.2    −9.6    2.3     −5.2   −5.5   −0.3
   SD                            12.3      13.4     11.1    14.5    14.5    17.9   17.1   29.1
  Respiratory exchange ratio                                                              
   N                             29        24       26      27      23      25     25     27
   Mean                          −2.7      0        −4.0    −2.0    2.5     2.2    5.6    0.7
   SD                            10.4      11.7     10.7    10.3    13.8    8.7    13.4   11.5
  Time to peak VO~2~                                                                      
   N                             29        24       26      27      23      25     25     27
   Mean                          4.5       15.2     16.0    11.2    15.2    25.5   13.1   7.7
   SD                            34.9      26.3     22.9    28.6    65.7    35.7   33.4   33.0
  Total ventilation                                                                       
   N                             29        23       26      27      23      25     25     26
   Mean                          4.0       −2.8     4.5     6.1     14.2    15.3   14.7   11.3
   SD                            20.9      24.7     19.1    21.4    23.7    22.6   35.1   19.4
  End-tidal O~2~                                                                          
   N                             19        12       14      15      12      14     10     11
   Mean                          --1.5     --2.2    --1.2   --2.3   --1.5   0      0.5    --0.3
   SD                            3.9       3.8      3.2     5.8     4.3     3.1    3.5    4.0
  End-tidal CO~2~                                                                         
   N                             19        12       12      13      12      14     9      8
   Mean                          − 1.6     13.0     − 0.3   4.3     6.9     9.1    4.1    10.3
   SD                            9.3       18.2     6.6     13.9    14.2    18.9   17.8   33.4
  Anaerobic threshold                                                                     
   N                             26        20       22      25      20      22     21     22
   Mean                          5.7       8.3      9.7     6.6     4.6     −1.2   2.0    3.3
   SD                            25.2      26.6     28.5    24.0    25.0    23.1   29.5   29.4
  Percent predicted peak VO~2~                                                            
   N                             29        24       26      27      23      25     25     27
   Mean                          0.7       6.6      12.9    10.9    1.0     12.8   7.7    5.8
   SD                            16.0      19.7     19.4    16.4    20.2    22.7   34.5   23.6

\*Parenthesis show values for placebo-treated STARTS-1 patient subsequently randomised in STARTS-2 to sildenafil low, medium or high dose.

CO~2~, carbon dioxide production; CPET, cardiopulmonary exercise test; VE, ventilation; VO~2~, oxygen consumption.

![Mean change in peak oxygen consumption from baseline at (a) week 16 and (b) 1 year. At week 16, significant improvement was achieved in patients treated with medium-dose and high-dose sildenafil and there was no change in placebo-treated patients. At year 1, the placebo-treated patients had received sildenafil at low, medium or high dose since week 16. Only the low-dose patients had a significant increase in change in peak VO~2~ at 1 year.](openhrt-2019-001149f02){#F2}

![Mean change in the VE/VCO~2~slope at (a) week 16 and (b) 1 year in patients. Mean VE/VCO~2~ slope decreased (improved) compared with baseline in all sildenafil-treated patients at week 16. The change from baseline in the sildenafil groups combined versus placebo was statistically significant overall, and within each treatment group. At year 1, the placebo-treated patients had received sildenafil at low, medium or high dose since week 16. There was a sustained mean reduction in VE/VCO~2~ slope in sildenafil low and medium group but was not statistically significant.](openhrt-2019-001149f03){#F3}

There were 76 patients who received sildenafil and were developmentally able to exercise, and among them 43 (56.6%) had both an increase in PVO~2~ and a decrease in VE/VCO~2~ slope compared with their baseline. Twenty-nine developmentally able patients received placebo and among them 7 (24.1%) had both an increase in PVO~2~ and a decrease in VE/VCO~2~ slope compared with baseline.

1-year outcomes {#s3-2}
---------------

Two hundred and twenty (94%) out of 234 patients who randomised and treated in the STARTS-1 trial continued into STARTS-2. As shown in [figure 2b](#F2){ref-type="fig"}, there was a sustained increase in mean PVO~2~ at 1 year in all of the individual sildenafil dose groups compared with baseline, but only the low-dose group had a statistically significant mean increase of 12.4% (95% CI 3.0% to 21.8%,) ([Table 2](#T2){ref-type="table"}). Both the low-dose and medium-dose groups had a sustained numerical reduction in mean percent change in VE/VCO~2~ slope compared with baseline, but neither of these changes was statistically significant ([figure 3b](#F3){ref-type="fig"}); and there was no appreciable numerical change in the high-dose group in VE/VCO~2~ slope at year 1.

At 1 year, only 36 patients (36.7% out of 98 patients who had both PVO~2~ and VE/VCO~2~ slope data) had both an increase in PVO~2~ and a decrease in VE/VCO~2~ slope compared with baseline, suggesting progression of disease in the majority of the subjects. Consistency in changes from week 16 to 52 was observed for PVO~2~ with 73% of patients showing improvements or worsening at both week 16 and year 1. Patients who showed improvement at year 1 only included the placebo and low-dose sildenafil groups in STARTS-1. Only 63% of the patients had a consistent improvement or worsening for VE/VCO~2~ slope at weeks 16 and 52.

Safety {#s3-3}
------

The two primary reasons that patients were deemed 'unable to exercise' were age \<7 years or Down syndrome. There were no reports of difficulty performing the test or adverse events (ischaemia, arrhythmia) that prevented completion of the exercise test.

Discussion {#s4}
==========

In the first placebo-controlled, randomised trial of sildenafil versus placebo in children with PAH developmentally able to exercise, the combined sildenafil treatment groups did not show statistically significant improvement over placebo for PVO~2~ at week 16. However, the improvement in VE/VCO~2~ slope was statistically significantly better in the combined sildenafil group than placebo at week 16.

There have been few trials assessing exercise capacity in children with pulmonary hypertension. In adults, 6 MW distance has been used as the primary endpoint in almost all clinical trials of PAH drugs as it is believed to be an important predictor of outcome.[@R15] The major limitations to using the 6 MW test include variable effort, a learning effect from performing multiple times, day-to-day variation and the impact of comorbidities, all of which may be more important in children. CPET has been shown to be reproducible, predictive of outcomes and allows one to determine if a maximal test was performed.[@R16] Because of this, CPET might be a more objective test of exercise capacity in children. Additionally, the VE/VCO~2~ slope, an effort-independent value, might be especially useful for children who may not give a maximal effort. For adults, several measures obtained with CPET predict survival in patients with PAH, and CPET provides an objective assessment of true functional capacity as well as ventilatory inefficiency.[@R8] Miyamoto *et al* performed both tests in 27 patients and found a strong correlation between distance walked and PVO~2~, VE/VCO~2~ slope and oxygen pulse.[@R8] Lammers *et al* performed both tests in 41 children with PAH at an average age of 13 years.[@R17] They found a similar correlation between the exercise endpoints and distance walked. In our study, we found that PVO~2~ and VE/VCO~2~ slope both changed (improved) in the appropriate directions compared with placebo. Patients as young as 7 years old were able to perform maximal exercise tests as shown by achieving a high RER and the changes that occurred at week 16 were sustained over time. Clearly, CPET can be safely and adequately performed in children and thus measures made with CPET might be a better endpoint than a 6 MW test in this population.

The finding of an improvement in exercise capacity in children with PAH receiving sildenafil is similar to what has been demonstrated in prior studies. Humpl *et al* performed an open-label study of 14 children with PAH and found an increase in walk distance from 278+114 to 443+107 m at 6 months.[@R18] An improvement in 6 MW distance was also found in adults with sildenafil alone or as an addition to epoprostenol.[@R19] Oudiz *et al* evaluated the effects of 3 months of sildenafil on VE/VCO~2~ in 14 adults compared with 14 matched controls, showing a significant decrease in VE/VCO~2~ of 9±2 (mean±SE) in the sildenafil group compared with a non-significant increase in the controls.[@R20]

The effect of other PAH drugs on changes in exercise capacity in children has not been wellstudied. Intravenous epoprostenol has been studied in children and has been shown to be associated with an improvement in functional class and 6 MW distance.[@R21] Similarly, iloprost and treprostinil have been studied in children, although in very small studies. Three studies showed that children with PAH who had symptomatic improvement from these drugs all had an improvement in their 6 MW distance.[@R24] Finally, bosentan and ambrisentan have also been shown to produce improvements in functional class for those who also increased 6 MW distance.[@R27] Symptomatic improvement appears to track improvement in functional capacity for patients with PAH regardless of the therapy used.

This study is limited by the lack of a placebo control group beyond 16 weeks, and the inability of half of the patients to perform exercise. Furthermore, even though some children received therapy beyond 1 year, we do not have exercise data to assess if functional capacity improvements persisted beyond this point.

In conclusion, we have demonstrated that some children with PAH as young as 7 years of age are able to exercise and perform interpretable CPET. At 16 weeks compared with placebo, sildenafil tended to increase exercise capacity as measured by peak oxygen consumption and also showed a statistically significant improvement in ventilatory inefficiency, although these changes were not sustained by year 1. Larger and longerterm studies of sildenafil and other PAH drugs in the paediatric PAH population to assess long-term efficacy, optimal dosing and predictors of prognosis would be valuable. Ventilatory inefficiency may be a more reliable measure of change in exercise gas exchange in children with PAH. Finally, metabolic stress testing is safe and may be repeated multiple times in children with PAH.
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